Impact of Omnipod 5 automated insulin delivery on continuous glucose monitoring metrics and predictors of improvement in time in range
Authors' conclusion
Omnipod 5 is associated with significant and sustained improvements in CGM metrics and HbA1c, particularly in individuals with higher baseline HbA1c. The results suggest the potential benefits of prioritizing AID for individuals at greatest risk of complications.
Study context
- Population
- Adults with T1D using Omnipod 5 automated insulin delivery (AID) in a real-world setting
- Participants
- 353 adults
- Exposure
- Omnipod 5 AID use vs baseline
- Outcome
- CGM metrics and HbA1c after Omnipod 5 start
Methodological detailsreal-world, paired before-after comparison
- Real-world
- Paired before-after comparison
Main finding
As reported in the abstract
TIR change
+16%
p < 0.001
HbA1c change
−3 mmol/mol
p < 0.001
Observational data: associations, not effects.
Further findings
Time in full auto mode by sensor (Dexcom G6 vs Freestyle Libre 2 Plus)
P < 0.001
HbA1c change in baseline HbA1c ≥58 mmol/mol
- HbA1c change
- −7 mmol/mol, p < 0.001
Time in full auto mode by sensor (Dexcom G6 vs Freestyle Libre 2 Plus)
- Sensor choice did not affect likelihood of improved TIR or HbA1c
Predictors of improved HbA1c (logistic regression)
- Baseline HbA1c, OR per mmol/mol
- 1.24, p < 0.001
Predictors of improved TIR (logistic regression)
- Baseline TIR, OR per %
- 0.83, p < 0.001
- Greater time in automation and lowest glucose target also associated with improved outcomes
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →